By reiterating its adjusted EPS guidance for 2024, Zimmer Biomet demonstrates confidence in its financial performance and strategic direction. This reaffirmation is likely to be viewed positively by investors, as it aligns with analyst expectations and suggests stability in the company's operations and growth prospects. The close match with the consensus estimate indicates that the company's financial outlook is in line with market expectations, potentially leading to positive investor sentiment in the short term.